In the mass retailing firmament, the retailer is king. For industry suppliers, a primary objective is getting close to the retail merchants who make the key decisions affecting their products. There’s no new news in the previous paragraph.
If a new survey of pharmaceutical executives whose companies account for more than 40% of the industry’s global revenue is any indication, an era characterized by a remarkable level of innovation may be drawing to a close.
This issue of Chain Drug Review contains our annual look at America’s 100 largest drug store markets and the shares of the various drug store retailers within those markets. As is usually the case, this year’s analysis offers some surprises.
The muted reaction from the consumer press to the announcement by Walmart and Humana Inc. that they are offering a low-cost, co-branded prescription drug plan (PDP) for Medicare beneficiaries was puzzling.
almost 20 years after he left the drug chain he helped build into an iconic retailer — is the fact that
The Drug Enforcement Administration late last month sponsored a program to remove dangerous drugs from communities across the country.
No keener rivalry exists in all of retailing than that between CVS and Walgreens, America’s largest and most successful drug chains.
During the National Association of Chain Drug Stores’ Pharmacy and Technology Conference at the end of August, Steve Anderson, the organization’s president and chief executive officer, was heard to say that when it comes to health care reform he used to think we were in the fourth inning of a nine-i
The great American historian Henry Adams wrote, “Chaos often breeds life, when order breeds habit.” If that’s the case, retail pharmacy finds itself in an environment that makes the profession ripe for rejuvenation.
when his patients really insist — give advice about the drugs that he’s dispensing, the best and the brightest of today’s
A story about community pharmacists and their growing role in the nation’s health care system appeared on the front page of a Saturday edition of The New York Times earlier this month. Taking the work of Barney’s Pharmacy, an independent drug store in Augusta, Ga.
Though the year is barely half over, the major story of 2010 is clearly the retailer rush to pare assortments, popularly known as SKU rationalization. This exercise in reducing the number of items on retailer shelves has taken on a life of its own.
The Obama administration has begun the slow, laborious process of implementing the Affordable Care Act, legislation that will bring momentous changes to the nation’s health care system by the time its major provisions take effect in 2014.
Walgreen Co., CVS Caremark Corp. and Rite Aid Corp. — announced game-changing alterations. In that short span of time Walgreens acquired Duane Reade; Rite Aid reported that Mary Sammons, the retailer’s iconic chief executive,
CVS Caremark recently issued “Insights 2010: Evolving Pharmacy Care,” the latest in a series of annual reports about the role of prescription drugs in the nation’s health care system as seen from the perspective of the company’s pharmacy benefits management operation.
